Conclusion
The infrastructure of the EURAS-HRT study has been successfully established. The study design permits robust absolute risk estimates particular for cardiovascular
events.
Initial results do not indicate a high cardiovascular risk potential of drospirenone/estradiol compared to other oral HRT preparations.
